Screener
Tarsus Pharmaceuticals, Inc. TARS Business Segments — Operating Income (Loss)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Selling and marketing | 90,002 | 65,857 | 174,484 | 126,143 |
| General and administrative | 60,695 | 37,156 | 112,642 | 61,865 |
| Total operating expenses | 193,820 | 124,844 | 361,996 | 229,459 |
| Loss from operations | (19,908) | (22,184) | (26,030) | (48,464) |
| Other reconciling items(1) | 1,357 | 1,844 | 512 | 3,004 |
| Net loss | $(18,551) | $(20,340) | $(25,518) | $(45,460) |
| Other segment disclosures: | ||||
| Interest income | $3,698 | $4,229 | $7,420 | $7,683 |
Item 1. Financial Statements
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s business segments — operating income (loss)?
- Tarsus Pharmaceuticals, Inc. (TARS) reported business segments — operating income (loss) of -$19.91M in Q2 2026.
- How has Tarsus Pharmaceuticals, Inc.'s business segments — operating income (loss) changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s business segments — operating income (loss) increased by 10.3% year-over-year, from -$22.18M to -$19.91M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s business segments — operating income (loss)?
- Over 3 years (2022 to 2025), Tarsus Pharmaceuticals, Inc.'s business segments — operating income (loss) has grown at a 4.2% compound annual growth rate (CAGR), from -$62.71M to -$70.97M.
- What does business segments — operating income (loss) mean?
- Measures the profitability of the business segment by subtracting total operating expenses from total revenues. It indicates the core operational viability and the ability of the segment to generate profit from its primary business activities.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s business segments — operating income (loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude